In Situ Bone Tissue Engineering With an Endogenous Stem Cell Mobilizer and Osteoinductive Nanofibrous Polymeric Scaffolds

Jong Seung Lee, Yoonhee Jin, Hyun Ji Park, Kisuk Yang, Min Suk Lee, Hee Seok Yang, Seung-Woo Cho

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Classical bone tissue engineering involves the use of culture-expanded cells and scaffolds to produce tissue constructs for transplantation. Despite promising results, clinical adoption of these constructs has been limited due to various drawbacks, including extensive cell expansion steps, low cell survival rate upon transplantation, and the possibility of immuno-rejection. To bypass the ex vivo cell culture and transplantation process, the regenerative capacity of the host is exploited by mobilizing endogenous stem cells to the site of injury. Systemic injection of substance P (SP) induce mobilization of CD29+ CD105+ CD45 cells from bone marrow and enhance bone tissue regeneration in a critical-sized calvarial bone defect model. To provide an appropriate environment for endogenous stem cells to survive and differentiate into osteogenic lineage cells, electrospun nanofibrous polycaprolactone (PCL) scaffolds are functionalized with hydroxyapatite (HA) particles via a polydopamine (PDA) coating to create highly osteoinductive PCL-PDA-HA scaffolds that are implanted in defects. The combination of the PCL-PDA-HA scaffold and SP treatment enhance in situ bone tissue formation in defects. Thus, this in situ bone regeneration strategy, which combines recruitment of endogenous stem cells from the bone marrow to defective sites and implantation of a highly biocompatible and osteoinductive cell-free scaffold system, has potential as an effective therapeutic in regenerative medicine.

Original languageEnglish
Article number1700062
JournalBiotechnology Journal
Volume12
Issue number12
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Tissue Engineering
Stem Cells
Durapatite
Bone and Bones
Bone Regeneration
Substance P
Cell Culture Techniques
Tissue Transplantation
Regenerative Medicine
Cell-Free System
Cell Transplantation
Osteogenesis
Bone Marrow Cells
Cell Survival
Transplantation
Bone Marrow
Injections
Wounds and Injuries
Therapeutics
polycaprolactone

All Science Journal Classification (ASJC) codes

  • Applied Microbiology and Biotechnology
  • Molecular Medicine

Cite this

Lee, Jong Seung ; Jin, Yoonhee ; Park, Hyun Ji ; Yang, Kisuk ; Lee, Min Suk ; Yang, Hee Seok ; Cho, Seung-Woo. / In Situ Bone Tissue Engineering With an Endogenous Stem Cell Mobilizer and Osteoinductive Nanofibrous Polymeric Scaffolds. In: Biotechnology Journal. 2017 ; Vol. 12, No. 12.
@article{eb44adae1fa34ff48e35004e83936afc,
title = "In Situ Bone Tissue Engineering With an Endogenous Stem Cell Mobilizer and Osteoinductive Nanofibrous Polymeric Scaffolds",
abstract = "Classical bone tissue engineering involves the use of culture-expanded cells and scaffolds to produce tissue constructs for transplantation. Despite promising results, clinical adoption of these constructs has been limited due to various drawbacks, including extensive cell expansion steps, low cell survival rate upon transplantation, and the possibility of immuno-rejection. To bypass the ex vivo cell culture and transplantation process, the regenerative capacity of the host is exploited by mobilizing endogenous stem cells to the site of injury. Systemic injection of substance P (SP) induce mobilization of CD29+ CD105+ CD45− cells from bone marrow and enhance bone tissue regeneration in a critical-sized calvarial bone defect model. To provide an appropriate environment for endogenous stem cells to survive and differentiate into osteogenic lineage cells, electrospun nanofibrous polycaprolactone (PCL) scaffolds are functionalized with hydroxyapatite (HA) particles via a polydopamine (PDA) coating to create highly osteoinductive PCL-PDA-HA scaffolds that are implanted in defects. The combination of the PCL-PDA-HA scaffold and SP treatment enhance in situ bone tissue formation in defects. Thus, this in situ bone regeneration strategy, which combines recruitment of endogenous stem cells from the bone marrow to defective sites and implantation of a highly biocompatible and osteoinductive cell-free scaffold system, has potential as an effective therapeutic in regenerative medicine.",
author = "Lee, {Jong Seung} and Yoonhee Jin and Park, {Hyun Ji} and Kisuk Yang and Lee, {Min Suk} and Yang, {Hee Seok} and Seung-Woo Cho",
year = "2017",
month = "12",
day = "1",
doi = "10.1002/biot.201700062",
language = "English",
volume = "12",
journal = "Biotechnology Journal",
issn = "1860-6768",
publisher = "Wiley-VCH Verlag",
number = "12",

}

In Situ Bone Tissue Engineering With an Endogenous Stem Cell Mobilizer and Osteoinductive Nanofibrous Polymeric Scaffolds. / Lee, Jong Seung; Jin, Yoonhee; Park, Hyun Ji; Yang, Kisuk; Lee, Min Suk; Yang, Hee Seok; Cho, Seung-Woo.

In: Biotechnology Journal, Vol. 12, No. 12, 1700062, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In Situ Bone Tissue Engineering With an Endogenous Stem Cell Mobilizer and Osteoinductive Nanofibrous Polymeric Scaffolds

AU - Lee, Jong Seung

AU - Jin, Yoonhee

AU - Park, Hyun Ji

AU - Yang, Kisuk

AU - Lee, Min Suk

AU - Yang, Hee Seok

AU - Cho, Seung-Woo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Classical bone tissue engineering involves the use of culture-expanded cells and scaffolds to produce tissue constructs for transplantation. Despite promising results, clinical adoption of these constructs has been limited due to various drawbacks, including extensive cell expansion steps, low cell survival rate upon transplantation, and the possibility of immuno-rejection. To bypass the ex vivo cell culture and transplantation process, the regenerative capacity of the host is exploited by mobilizing endogenous stem cells to the site of injury. Systemic injection of substance P (SP) induce mobilization of CD29+ CD105+ CD45− cells from bone marrow and enhance bone tissue regeneration in a critical-sized calvarial bone defect model. To provide an appropriate environment for endogenous stem cells to survive and differentiate into osteogenic lineage cells, electrospun nanofibrous polycaprolactone (PCL) scaffolds are functionalized with hydroxyapatite (HA) particles via a polydopamine (PDA) coating to create highly osteoinductive PCL-PDA-HA scaffolds that are implanted in defects. The combination of the PCL-PDA-HA scaffold and SP treatment enhance in situ bone tissue formation in defects. Thus, this in situ bone regeneration strategy, which combines recruitment of endogenous stem cells from the bone marrow to defective sites and implantation of a highly biocompatible and osteoinductive cell-free scaffold system, has potential as an effective therapeutic in regenerative medicine.

AB - Classical bone tissue engineering involves the use of culture-expanded cells and scaffolds to produce tissue constructs for transplantation. Despite promising results, clinical adoption of these constructs has been limited due to various drawbacks, including extensive cell expansion steps, low cell survival rate upon transplantation, and the possibility of immuno-rejection. To bypass the ex vivo cell culture and transplantation process, the regenerative capacity of the host is exploited by mobilizing endogenous stem cells to the site of injury. Systemic injection of substance P (SP) induce mobilization of CD29+ CD105+ CD45− cells from bone marrow and enhance bone tissue regeneration in a critical-sized calvarial bone defect model. To provide an appropriate environment for endogenous stem cells to survive and differentiate into osteogenic lineage cells, electrospun nanofibrous polycaprolactone (PCL) scaffolds are functionalized with hydroxyapatite (HA) particles via a polydopamine (PDA) coating to create highly osteoinductive PCL-PDA-HA scaffolds that are implanted in defects. The combination of the PCL-PDA-HA scaffold and SP treatment enhance in situ bone tissue formation in defects. Thus, this in situ bone regeneration strategy, which combines recruitment of endogenous stem cells from the bone marrow to defective sites and implantation of a highly biocompatible and osteoinductive cell-free scaffold system, has potential as an effective therapeutic in regenerative medicine.

UR - http://www.scopus.com/inward/record.url?scp=85030309220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030309220&partnerID=8YFLogxK

U2 - 10.1002/biot.201700062

DO - 10.1002/biot.201700062

M3 - Article

C2 - 28925552

AN - SCOPUS:85030309220

VL - 12

JO - Biotechnology Journal

JF - Biotechnology Journal

SN - 1860-6768

IS - 12

M1 - 1700062

ER -